Alnylam Pharmaceuticals (ALNY) Non-Current Deffered Revenue (2009 - 2024)

Alnylam Pharmaceuticals has reported Non-Current Deffered Revenue for 16 years, with the latest figure at $1.0 million in Q3 2024.

• For the quarter ending Q3 2024, Non-Current Deffered Revenue fell 99.48% year-over-year to $1.0 million; the trailing twelve-month figure through Sep 2024 stood at $1.0 million (down 99.48% YoY), and the FY2023 full-year result was $188.2 million, down 2.9% from the prior year.
• Non-Current Deffered Revenue for Q3 2024 stood at $1.0 million, down from $2.4 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $306.1 million in Q1 2020, with the low at $1.0 million in Q3 2024.
• Historically, Non-Current Deffered Revenue has averaged $180.9 million across 5 years, with a median of $191.3 million in 2023.
• Annual changes were most pronounced in 2020 — Non-Current Deffered Revenue jumped 63942.68% — and 2024, when it tumbled 99.48%.
• Alnylam Pharmaceuticals' Non-Current Deffered Revenue stood at $225.1 million in 2020, then tumbled by 32.31% to $152.4 million in 2021, then climbed by 27.19% to $193.8 million in 2022, then declined by 2.9% to $188.2 million in 2023, then tumbled by 99.46% to $1.0 million in 2024.
• The last three Non-Current Deffered Revenue figures came in at $1.0 million (Q3 2024), $2.4 million (Q2 2024), and $185.5 million (Q1 2024), per Business Quant data.